These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21107549)

  • 21. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
    Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
    Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
    Yoo RE; Choi SH; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2015 Oct; 36(10):1846-52. PubMed ID: 26294653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
    Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
    J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
    Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
    Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.
    Alcaide-Leon P; Luks TL; Lafontaine M; Lupo JM; Okada H; Clarke JL; Villanueva-Meyer JE
    J Neurooncol; 2020 Jan; 146(1):71-78. PubMed ID: 31728884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR imaging of glioblastoma in children: usefulness of diffusion/perfusion-weighted MRI and MR spectroscopy.
    Chang YW; Yoon HK; Shin HJ; Roh HG; Cho JM
    Pediatr Radiol; 2003 Dec; 33(12):836-42. PubMed ID: 14564423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastoma--Report of two exceptional cases.
    Floeth FW; Wittsack HJ; Engelbrecht V; Weber F
    Zentralbl Neurochir; 2002; 63(1):23-8. PubMed ID: 12098080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes after Glioblastoma Resection: MRI within 48 Hours vs. beyond 48 Hours.
    Negroni D; Bono R; Soligo E; Longo V; Cossandi C; Carriero A; Stecco A
    Tomography; 2023 Feb; 9(1):342-351. PubMed ID: 36828379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.
    Jajamovich GH; Valiathan CR; Cristescu R; Somayajula S
    J Neurooncol; 2016 Sep; 129(2):289-300. PubMed ID: 27393347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma.
    Yoon RG; Kim HS; Kim DY; Hong GS; Kim SJ
    Eur Radiol; 2016 Apr; 26(4):1037-47. PubMed ID: 26159871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
    Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions.
    Lee EJ; terBrugge K; Mikulis D; Choi DS; Bae JM; Lee SK; Moon SY
    AJR Am J Roentgenol; 2011 Jan; 196(1):71-6. PubMed ID: 21178049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach.
    Neska-Matuszewska M; Bladowska J; Sąsiadek M; Zimny A
    PLoS One; 2018; 13(1):e0191341. PubMed ID: 29342201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.